Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
22 November 2021 - 03:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
November 22, 2021
(Commission File No. 001-40505)
Ambrx Biopharma Inc.
(Translation of registrants name into English)
Cayman
Islands
(Jurisdiction of incorporation or organization)
10975 Torrey Pines Road
La Jolla, California 92037
(Address of registrants principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On November 15, 2021, Joy Yan, M.D., Ph.D., our Chief Medical Officer, informed us of her intent to
resign effective January 4, 2022, to pursue another employment opportunity. Dr. Yan has agreed to continue providing services to Ambrx as a member of our Scientific Advisory Board following her last day of employment.
On November 16, 2021, Chris Nolet resigned as a member of our Board of Directors. Mr. Nolet confirmed to us that he has no knowledge of any
matters that would suggest our condensed consolidated financial statements and notes thereto included in our Form 6-K filed on October 28, 2021 are not presented fairly in all
material respects.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereto duly authorized.
|
|
|
Ambrx Biopharma Inc.
|
|
|
By:
|
|
/s/ Feng Tian
|
Name:
|
|
Feng Tian, Ph.D.
|
Title:
|
|
Chief Executive Officer
|
Date: November 22, 2021
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2023 bis Mär 2024